Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.
Brief summary
This study will seek to determine the (1) acceptability and (2) feasibility of psilocybin as an adjunct to cognitive-behavioral therapy, delivered as a group treatment (G-PACBT) for major depressive disorder and (3) explore the clinical effects of G-PACBT on depressive symptoms and psychosocial functioning.
Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.
Trial details
- status
- NOT_YET_RECRUITING
- phase
- PHASE2
- study type
- INTERVENTIONAL
- enrollment
- 30
- sponsor
- University of California, Los Angeles
- conditions
- Depression - Major Depressive Disorder; Psilocybin; Cognitive Behavioral Therapy
- interventions
- DRUG: Psilocybin (drug); BEHAVIORAL: Group Cognitive Behavioral Therapy
- start date
- 2027-01-01
- start date type
- ESTIMATED
- primary completion date
- 2028-12-01
- has results
- false
- data source
- ClinicalTrials.gov
- data processed
- 2026-10-29T09:00:05
- modifications
- selected fields only; whitespace normalized; brief summary truncated to 2,000 characters
Record
- Archive ID
- nct:NCT07566104
- Published
- May 4, 2026
- Venue
- ClinicalTrials.gov
- ClinicalTrials.gov
- NCT07566104
- Categories
- Depression - Major Depressive Disorder, Psilocybin, Cognitive Behavioral Therapy
- License
- ClinicalTrials.gov terms (attribution, processing date, modifications noted)
- Provenance
- clinicaltrials